AllSci News
Click Therapeutics closes USD 50m Series D led by Boehringer for prescription digital device
New York-based Click Therapeutics has closed a Series D round anchored by a USD 50 million strategic investment from Boehringer Ingelheim, alongside...
C4 Therapeutics, Roche expand partnership on degrader-antibody conjugates in USD 1b+ deal
C4 Therapeutics, Inc. (Nasdaq: CCCC), a Watertown, Massachusetts-based clinical-stage biopharmaceutical company, has entered into a new collaboration agreement with Roche (SIX: RO,…
Trogenix's Nature publication highlights 83% tumor eradication via SSE gene therapy in glioblastoma models
Trogenix (Edinburgh) reported preclinical data published in Nature showing that a single dose of its Synthetic Super-Enhancer (SSE) gene therapy achieved...
Gilead licenses Kymera's oral CDK2 molecular glue degrader KT-200 for USD 45m milestone
KT-200, an oral CDK2 molecular glue degrader discovered by Kymera Therapeutics (NASDAQ: KYMR), has moved closer to the clinic after Gilead Sciences (NASDAQ:...
Shionogi secures USD 482 million BARDA Project BioShield contract for Fetroja
Shionogi's New Jersey subsidiary has secured a contract through BARDA's Project BioShield program worth an initial USD 119 million, with multiyear options...
23andMe identifies genetic predictors of GLP-1 weight loss and side effects in Nature study
23andMe researchers report genetic predictors of GLP-1 receptor agonist weight loss and side effects in Nature
Basilea receives USD 6 million CARB-X funding for BAL2420 antibiotic development
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland, has received an additional USD...
Forte Biosciences raises USD 150m in public offering
Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) announced the pricing of a USD 150 million public offering on April 8, 2026, with proceeds directed...
Life Biosciences secures USD 80 million Series D to advance ER-100 gene therapy
Boston-based Life Biosciences has closed a USD 80 million Series D financing round to advance ER-100, its lead gene therapy candidate for optic...
Astellas exercises USD 15m option on Dyno's AI-designed AAV capsid for skeletal muscle gene delivery
An AI-designed AAV capsid engineered for skeletal muscle gene delivery has moved from option to full license, with Astellas Pharma (TSE: 4503) exercising...
Cue Bio takes USD 7.5m milestone from Boehringer Ingelheim for bispecific B cell depleter
CUE-501, a preclinical bispecific fusion protein biologic described by Cue Biopharma (NASDAQ: CUE) as designed to selectively deplete pathogenic B cells via...
Luye Pharma starts China Phase II for TAAR1/5-HT2CR dual agonist in schizophrenia
Luye Pharma announced on April 8 that the first subject has been enrolled in the Phase II clinical trial in China of LY03020, an oral controlled-release...
Plus Therapeutics’ Reyobiq wins FDA Orphan Drug Designation for pediatric malignant gliomas
Plus Therapeutics (Nasdaq: PSTV) announced receipt of orphan drug designation from the FDA for Reyobiq (rhenium Re186 obisbemeda) for pediatric malignant gliomas,…
Nuvalent's files with FDA for neladalkib in TKI pre-treated ALK-positive lung cancer
Nuvalent submitted a New Drug Application to the US FDA on April 7, 2026, for neladalkib, an investigational ALK-selective tyrosine kinase inhibitor,...
Neurocrine target Soleno withdraws EU market approval filing for Viokat
Note to editor: The source material concerns a regulatory withdrawal, not a submission or approval filing. The article has been written to accurately...
The AllSci Brief
Systematic R&D and deal news. Daily.